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Given the increases in 5-year cancer survival and recent advances in fertility preserving technologies, an increasing number of
women with cancer are presenting for discussion of fertility preserving options. This review will summarize the risk of infertility
secondary to cancer treatment, available treatment options for fertility preservation, and techniques to reduce future risks for
patients. Concerns that will be addressed include the risk of the medications and procedures, the potential delay in cancer
treatment, likelihood of pregnancy complications, as well as the impact of future pregnancy on the recurrence risk of cancer.
Recent advances in oocyte cryopreservation and ovarian stimulation protocols will be discussed. Healthcare providers need to
be informed of available treatment options including the risks, advantages, and disadvantages of fertility preserving options to
properly counsel patients.
1.Introduction
Anestimated1outof47womenwillbediagnosedwithsome
type of invasive cancer by age 40 years, and approximately
774,370 women will be diagnosed with cancer in 2011 [1].
The most common cancers in reproductive age women
are breast, melanoma, cervical cancer, non-Hodgkin’s lym-
phoma, and leukemia [2]. Fortunately, the 5-year relative
survival for all cancers is up from 50% (1975–1977) to 68%
(1999–2006) reﬂecting improved diagnosis and treatment.
The 5-year female cancer survival is dependent on stage at
diagnosisbutiscurrently90%forbreast,91%formelanoma,
71%forcervical,69%non-Hodgkinlymphoma,and55%for
leukemia [1]. Given the relatively high incidence of cancer
in reproductive age women and improvements in 5-year
survival, an increasing number of women are presenting
for discussion of fertility preservation and pregnancy after
cancer treatment.
Fertility preservation is a rapidly evolving ﬁeld that
includes medical and surgical treatments to decrease the
impact of cancer treatments on future fertility. Traditional
fertility preserving techniques for patients undergoing radi-
ation treatment included pelvic shielding or surgical reposi-
tioning of the ovaries out of the pelvis. Medical treatments
to suppress ovarian function during chemotherapy have also
been reported to decrease the eﬀect on cancer treatments
on future ovarian function. These modalities still rely on
residualovarianfunctionaftercancertreatmentstoconceive.
Newer techniques to preserve ovarian reserve, oocytes, and
embryos prior to cancer treatments have been developed to
provide an opportunity to conceive in the event that cancer
treatments result in permanent loss of ovarian function.
This review will summarize available treatment options
for fertility preservation in cancer patients. Concerns that
will be addressed include the risk of the medications and
procedures,thepotentialdelayincancertreatment,aswellas2 Obstetrics and Gynecology International
the impact of future pregnancy on the recurrence risk of
cancer. Healthcare providers need to be aware of available
treatment options including the risks, advantages, and dis-
advantagesoffertility-preservingoptionstoproperlycounsel
patients.
2.Methods and Materials
We performed a MEDLINE search to July 2011 using
the following terms: fertility preservation, cancer, in vitro
fertilization, assisted reproduction, ovarian stimulation,
oocyte vitriﬁcation, ovarian preservation, hereditary can-
cer, childhood cancer, preimplantation genetic diagnosis,
ovarian reserve, pregnancy, and cancer. Studies included
in this review include publications in peer-reviewed jour-
nals.
3. Results andDiscussion
3.1. Counseling Patients on Future Fertility Prior to Cancer
Therapy. Future fertility is a signiﬁcant concern for patients
undergoing cancer treatment. Studies have shown that the
psychological impact of cancer-related infertility is substan-
tial with 77% of patients reporting clinically signiﬁcant levels
of distress in relation to loss of fertility [3]. A survey of over
600 women with breast cancer indicated that 73% of women
reported some degree of concern about the possibility of
becoming infertile after treatment and 29% of patients
indicated that their desire for future fertility impacted their
cancer treatment decisions. In fact, many women indicated
that they may choose a less toxic dose of chemotherapy to
helppreservefertilityevenifitmayincreasetheriskofcancer
recurrence [4]. Cancer survivors also have higher depres-
sion and distress scores if they have unmet informational
needs about future reproductive options [5]. Recognizing
these concerns, the American Society of Clinical Oncology
(ASCO) published recommendations in 2006 on fertility
preservation in cancer patients. These guidelines state that
oncologists should address the possibility of infertility with
cancer patients and be prepared to discuss possible fertility
preservation options or refer the patient to a reproductive
specialist [6].
Despite the 2006 ASCO recommendations, a nationwide
survey of oncologists in 2009 reported that less than 50%
referred patients to a reproductive specialist [7]. A survey
of academic medical centers reported similar results with
less than 40% referring patients to a reproductive specialist
although 95% reported that they routinely discussed the
eﬀect of cancer treatment on fertility [8]. Factors that were
associated with a higher likelihood to refer in patients with
breast cancer included patients with a family history of
breast cancer, older age, early stage cancer, and receiving care
at an academic center [9]. Interestingly, a review of NIH
intramural clinical trials for pediatric cancer, gynecologic
cancer, or for stem-cell transplantation found that only 47%
of patient consents addressed future infertility risks after
cancer treatment [10].
3.1.1. Risk of Infertility after Cancer Treatment. The adverse
eﬀects of chemotherapy and radiotherapy on female repro-
duction have long been recognized. Part of the diﬃculty in
counseling patients regarding the risk of infertility and/or
subsequent pregnancy complications is that the risks are
dependent on several factors. These risks include the dose
and duration of treatment, other risk factors for infertility,
the age of the patient, and the patient’s baseline ovarian
reserve at the time of initiation of treatment.
Pelvic and/or abdominal radiation impacts future fertil-
i t yb ya ﬀecting both uterine and ovarian function. Radiation
is typically administered as external beam therapy (telether-
apy), intracavitary (brachytherapy), or total body irradiation
as is utilized with stem-cell transplantation. Radiation is
most commonly used in children for treatment of Wilm’s
tumor, abdominal rhabdomyosarcoma, and Ewing’s sarcoma
of the pelvis or spine. The eﬀects of radiation therapy are
dependent on the dose and the ﬁeld applied. Radiation is
typically targeted at the aﬀected area; however, the impact of
scattered radiation during treatments is also a consideration.
Total body irradiation as used in stem-call transplantation
has an over 80% risk of permanent amenorrhea. Limited
ﬁeld external beam radiation has a reduced risk depending
on the location, dose, fractionation schedule, and age of the
patient at the time of radiation treatment. In a study of 2000
women treated with pelvic radiotherapy, 95% had perma-
nentovarianfailurefollowingradiotherapyof5–105Gy[11].
It was reported that radiation doses over 5Gy for women
over 30 years results in permanent amenorrhea, however, it
has been reported more recently that the lethal dose (LD50)
of the human oocyte is actually less than 2Gy [12].
Although the uterus is relatively resistant to the eﬀect of
radiotherapy, there is a concern that radiation may decrease
uterine blood supply, volume, and endometrial thickness.
Exposure to 20–30Gy of abdominal or pelvic radiation
has been shown to increase the future risk of miscarriage,
preterm labor, and low birth weight [13]. The impact of
radiation on future uterine function is dependent on the age
at radiation in childhood cancers. The prepubertal uterus
appears to be more vulnerable to the eﬀects of radiation.
Hormonal stimulation with estrogen and progesterone to
improve endometrial thickness, and blood ﬂow after radia-
tion has been evaluated with variable eﬀectiveness. The uter-
ine volume increased signiﬁcantly from 6.5mL to 16.3mL
but was still less than controls after 3 months of hormonal
replacement provided to patients with amenorrhea after
radiation treatments. It was noted than patients exposed to
prepubertal radiation had less improvement that patients
exposed postpubertally [14]. Another study evaluating 3
childhood cancer survivors that received high-dose abdomi-
nal or pelvic radiation (30–54Gy) found no increase in uter-
ine volume, blood ﬂow, or endometrial thickness with high-
dose estrogen therapy [15]. These limited studies indicate
that higher dosages of radiation aﬀect uterine function and
aremostsigniﬁcantifadministeredprepubertally.Hormonal
therapy may have limited beneﬁt for improving endometrial
development and patients that conceive should be con-
sidered at higher risk of preterm labor, delivery, and low-
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The primary impact of chemotherapy on fertility is
related directly to the loss of ovarian function secondary to
the gonadotoxicity of many chemotherapeutic agents. Cell-
cyclenonspeciﬁcalkylatingagentssuchascyclophosphamide
will destroy resting primordial oocytes while antimetabo-
lite agents (methotrexate) have limited eﬀect on ovarian
function. The greatest risk is in women over age 40 years
receiving alkylating agents with up to 80% of patients
having permanent amenorrhea after treatment. However, in
women under 30 years, the risk of permanent amenorrhea
is substantially decreased to less than 20% [6]. The eﬀect
of chemotherapy will also depend on whether it is radical
or adjuvant, single agent, or combination. Fortunately,
the more recent ABVD regimen (Doxorubicin, Bleomycin,
Vincristine, and Dacarbazine) used in the treatment of
Hodgkin’sdiseaseissigniﬁcantlylesstoxictofertilitythanthe
older MOPP (Mechlorethamine, Vincristine, Procarbazine,
and Prednisilone). The classical CMF (Cyclophosphamide,
methotrexate, 5-ﬂuoruracil) regimen for breast cancer will
resultinover70%amenorrhearatesforwomenover40years
[16]. The newer Taxanes are still being evaluated for their
impact on fertility but hopefully will be less gonadotoxic
thancurrentlyusedregimens.Unfortunately,estimatesinthe
impact on fertility vary widely dependent on various factors,
and, therefore, there is no deﬁnitive predictor prior to
treatment making counseling on future fertility challenging
for health care providers.
3.1.2.DeterminingtheImpactofCancerTreatmentonOvarian
Reserve. The peak number of oocytes is found in females
at 20 weeks of fetal life, and this number declines until
menopause. The number of primordial follicles is approx-
imately 500,000 at menarche; menopause occurs once that
pool is nearly depleted. Although chronologic age is the
most important predictor of oocyte quality and quantity,
there is variability in the rate of ovarian aging. The term
“ovarian reserve” is used to describe remaining ovarian
oocyte quantity. Although menstrual cycles do not start
to become irregular until a mean age of 45 to 55 years,
endocrinologic changes associated with ovarian aging have
b e e nd e m o n s t r a t e df o rw o m e na g e3 5t o4 0y e a r sa n da t
earlier ages after cancer treatment. Several modalities have
been evaluated as markers of ovarian reserve including cycle
day 2-3 FSH, antimullerian hormone (AMH), and ovarian
ultrasound of antral follicles. Assessment of a patient’s
ovarian reserve both before and after cancer treatment may
provide valuable information for patients in discussion of
fertility preserving option prior to treatment and future
fertility after treatment.
Basal FSH values drawn during menstrual day 2-3 have
been the routinely utilized as a marker of ovarian reserve.
As FSH values increase, ovarian responsiveness decreases. An
FSH value of 10–15IU/L is generally considered borderline,
and values over 15IU/L are considered signiﬁcantly elevated
[17]. It is important when assessing FSH values to also
evaluatebasalestradiolasanelevationmaysuppressFSHand
give a falsely reassuring value. A normal basal estradiol may
vary between laboratories but typically is less than 60pg/mL.
FSH values may ﬂuctuate widely between cycles particularly
for patients with decreased ovarian reserve which limits its
eﬀectiveness as a marker of remaining ovarian function.
AMH is a member of the transforming growth factor
B family and is produced by the granulosa cells of the
secondary, prenatal, and antral follicles. AMH levels decrease
progressively until it becomes undetectable at menopause.
Theoretically, this may be a better marker of ovarian reserve
as it represents the number of early and developing follicles
and appears to have less intercycle variability than FSH [18].
One signiﬁcant advantage of this test is that it does not
require assessment on cycle day 2 or 3 since there is limited
variability during the menstrual. However, this test may not
beroutinely availableatalllaboratories, andnointernational
standard has been developed yet for this assay.
Ultrasound of ovarian follicle counts (AFC) has also
been evaluated as a tool for predicting ovarian reserve. The
number of antral follicles (<10mm) present on a menstrual
cycle day 2 to 3 by transvaginal ultrasound has also been
correlated with other serum markers of ovarian function
[19]. AFC is directly correlated with the number of oocytes
retrieved during IVF and may prove to be the best predictor
of ovarian reserve. Intercycle variability is present with all
forms of ovarian reserve testing, and no single test has been
consistently recommended. Basal FSH has been the mainstay
of screening, but basal AFC and AMH may prove to be
superior.
There is limited information on the impact of cancer
treatment on markers of ovarian reserve. Small studies in
young cancer patients have indicated that FSH, AMH and
AFC have all been demonstrated to change in response to
chemotherapy [20]. One study evaluated 42 premenopausal
women receiving neoadjuvant chemotherapy that were fol-
lowed over 5 years. Pretreatment FSH, AMH, and AFC
and all were found to reﬂect future ovarian activity for
women with menses after chemotherapy, but AMH was
the most predictive by logistic regression [21, 22]. Further
research is needed to determine the impact of cancer
treatmentsonmarkersofovarianreserveandanycorrelation
with future fertility. It is important to consider that most
research has evaluated these markers in relation to success
of ovarian stimulation for IVF; therefore, caution must be
used in counseling patients on the likelihood of spontaneous
pregnancy or with other fertility treatments.
3.2. Options for Fertility Preservation
3.2.1. Ovarian Suppression during Chemotherapy. It has been
well documented that chemotherapeutic agents, particularly
alkylatingagents,havehighlevelsofovariantoxicity.Oocytes
are contained in ovarian primordial follicles, and it is esti-
mated that hundreds to thousands of these follicles initiate
thematurationprocesseachmonthandaresusceptibletothe
gonadotoxic eﬀects of chemotherapy. Primordial follicles are
stimulated to initiate maturation through a complex process
thatisinitiatedbyfolliclestimulatinghormone(FSH)release
fromthepituitaryinresponsetohypothalamicgonadotropin
releasinghormone(GnRH).Suppressionofovarianfunction4 Obstetrics and Gynecology International
through manipulation of GnRH has been evaluated as a
mechanism to decrease the loss of primordial follicles.
Administration of GnRH analogs results in downregu-
lation of pituitary receptors within 10–14 days of adminis-
tration and subsequent suppression of FSH release. This has
been studied in animal models with promising results but
data regarding eﬀectiveness in humans is limited to small
retrospective reports. A recent systematic review [23]e v a l -
uating the utility of GnRH agonists in patients with breast
cancer summarized data on the 5 available nonrandomized
studies. The largest study of 100 women receiving 12 months
of GnRH analogs during cancer treatment found that 67%
of patients recovered normal menses with 100% return of
menstrual function for women less than 40 years of age.
However, only 3 pregnancies were reported [24]. Smaller
s t u d i e sh a v er e p o r t e dr e s u m p t i o no fm e n s e sf o r7 2 – 9 0 %o f
patients with several pregnancies reported.
Unfortunately, it cannot be determined from these
studies that the administration of GnRH agonists provided
deﬁnitive ovarian protection. There are 4 reported ongoing
prospective, randomized trials in women with hormone
receptor-negative breast cancer to evaluate the eﬀect on pre-
serving fertility [25]. Outcome data from these studies will
provide valuable information on the utility of this treatment
in preserving ovarian function. It should be noted that there
is some concerns regarding the use of GnRH agonists. It
has been suggested that GnRH agonists may decrease the
eﬀect of tamoxifen if administered simultaneously and until
more data is available, the ASCO recommends that women
interested in this treatment receive it only as part of an
approved clinical trial [6].
3.2.2. Embryo Cryopreservation. The basic principle of cry-
opreservation is to store cells or tissue for future use. Damage
to cells during the cryopreservation process has been a bar-
rier to the general use of this technology. Cryopreservation
is typically performed by incubation in a low concentration
of cryoprotectant to minimize ice crystal formation during
freezing; however, cells with a high osmotic content such as
oocytes are particularly vulnerable to damage. Embryos are
composed of multiple blastomere cells and are more stable
for cryopreservation. Due to the diﬃculties with oocyte
cryopreservation, embryo cryopreservation has been the
primary modality for fertility preservation and has been
available since the 1980s. The most recent available data
have indicated that over 21,000 embryo transfers occurred in
USA in 2009 from frozen, thawed embryos resulting in per-
cycle pregnancy rates of 35.6% 9 (<35 years), 30.9% (35–37
years), 26.8% (38–40 years), and 22.1% (40–42 years) with
an average of approximately two embryos transferred per
patient (http://www.sart.org/).
Embryo banking has several advantages for patients
interested in preserving fertility. It provides reassurance to a
patient that she will have some potential to conceive if the
cancer treatments result in permanent amenorrhea. There
is also over 20 years of outcome data for cryopreserved
embryos showing no eﬀect on miscarriage, implantation
rates, or live birth [26]. A disadvantage of embryo banking
is the need to administer ovarian stimulation medications
to obtain oocytes for fertilization. Ovarian stimulation is
a particular concern for patients with hormonal sensitive
tumors such as breast cancer and will be addressed further
in this review.
The American Society for Reproductive Medicine
(ASRM) Ethics Committee published guidelines in 2005 on
fertility preservation and reproduction in cancer patients.
These guidelines state that the only established method of
female fertility preservation is embryo cryopreservation and
thatexperimentalproceduressuchasoocyteorovariantissue
cryopreservation should be oﬀered only in a research setting
with IRB oversight [27]. However, these recommendations
may be revised with improvements in oocyte preservation
technology and increasing numbers of live birth reported in
the past several years.
3.2.3. Oocyte Cryopreservation. Recent advances in oocyte
cryopreservation technology have expanded the use of
this technology for fertility preservation. Disadvantages are
similar to those of embryo banking including the risk of
ovarian stimulation for patients with hormonally responsive
cancers and the potential delay in starting cancer treatments.
Oocyte banking is preferable over embryo banking for
patients that do not have a partner and/or are not interested
in utilizing donor sperm or have ethical concerns regarding
cryopreservation of embryos.
Until recently, the primary disadvantage of oocyte bank-
ing has been the lower success rate compared to embryo
cryopreservation. The ﬁrst pregnancy from oocyte cryop-
reservation was reported in 1986 [28], but few pregnancies
were subsequently reported due to poor survival rates for
oocytes. The poor survival rates for oocytes that have been
cryopreserved and thawed are attributable to several factors.
Oocytes have a relatively high volume compared to other
cells and are susceptible to intracellular ice crystal formation.
Cryopreservation of oocytes has also been shown to result in
chromosome and DNA abnormalities as the meiotic spindle
of oocytes is very sensitive to chilling. Oocytes are also
more susceptible to damage from reactive oxygen species
than other cells. Many of these parameters improve after
fertilization,makingembryoslesssusceptibletodamagethan
oocytes [29].
T h em o r er e c e n td e v e l o p m e n to fo o c y t ev i t r i ﬁ c a t i o n
incorporates several modiﬁcations to traditional cryopreser-
vation that result in less toxicity to oocytes. Oocyte vitriﬁ-
cation exposes oocytes to higher concentrations of cryopro-
tectants for shorter durations of time followed by very rapid
cooling. There have been over 500 pregnancies reported
worldwide since 2005 with improvements in oocyte cryop-
reservation techniques [30]. A meta-analysis of randomized
controlled trials assessing eﬃcacy of oocyte vitriﬁcation
reported similar fertilization, embryogenesis, and pregnancy
from oocytes derived from vitriﬁed oocytes compared to
fresh oocytes. The authors state that increasing reports of
successful cryopreservation of oocytes warrant reexamina-
tionofwhetheroocytevitriﬁcationshouldstillbeconsidered
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3.2.4. Ovarian Tissue Cryopreservation. Ovarian tissue cry-
opreservation has also been evaluated as a modality to
preserve future fertility. A portion of ovarian cortex is cry-
opreserved and then transplanted back to the pelvis, or other
location (arm or abdominal wall has been reported) [32, 33].
The ﬁrst report of an ovarian transplant operation occurred
in 2000 [34] with the ﬁrst pregnancy reported in 2004 [35]
inapatientwithnon-Hodgkin’slymphoma.Therehavebeen
fewer than 15 reported pregnancies worldwide with this
technique; however, the ﬁrst report of a woman that gave
birth to a second child by natural conception after ovarian
tissue transplantation has recently been reported [36].
Advantages of ovarian tissue transplantation include that
it can be performed in prepubertal girls and adolescents, can
be performed at any point in the menstrual cycle, has the
potential to save large numbers of oocytes, and may allow
for spontaneous pregnancy in the future without in vitro
fertilization or ovarian stimulation. Disadvantages include
the need for surgery (typically by laparoscopy) to remove
the tissue and risk of graft failure. There is also some evi-
dence that oocyte quality may be compromised with lower
than expected fertility rates even with IVF. Another very
signiﬁcant concern which may limit its usefulness for cancer
patients include the possibility of contamination of ovarian
tissue by malignant cells which has been reported with
hematologic cancers and Ewing’s sarcoma [21, 22].
Patients undergoing ovarian tissue cryopreservation may
still require future ovarian stimulation with gonadotropins
and/or in vitro fertilization. Options that have been inves-
tigated to eliminate the risk of exposure to gonadotropins
include in vitro maturation, (IVM) or in follicle maturation
(IFM) of oocytes. These techniques require surgical removal
of immature oocytes followed by in vitro exposure to
gonadotropinstomatureoocytesoutsidethebody.Therehas
been limited success with this approach utilizing immature
oocytes aspirated during either the follicular or luteal phase
of the menstrual cycle and matured in vitro. Although the
survival rate is lower than with oocytes matured in vivo and
vitriﬁed, survival rates of 67.5% and clinical pregnancy rates
of 20% have recently been reported [37]. Further data is
needed to determine if this will be an eﬀective treatment
option for patients.
3.2.5. Recent Developments in IVF for Cancer Patients. Until
recently, preserving oocytes or embryos have required a
delay in cancer treatment of up to 4–6 weeks to complete
the IVF cycle. Traditional ovarian preparation for IVF
required 10–14 days of ovarian stimulation with exogenous
gonadotropins preceded by ovarian suppression with GnRH
agonists for approximately 2 weeks to prevent premature
ovulation. Medications were initiated in the luteal phase of
the cycle which may add up to 3 additional weeks to the
process depending on when the patient presents for treat-
ment.
Recent advances that include the development of GnRH
antagonists have signiﬁcantly decreased the interval from
patient presentation to gamete cryopreservation. In contrast
to GnRH agonists, GnRH antagonists immediately suppress
pituitary release of FSH and LH and do not require the 10–
14 days of administration prior to gonadotropin initiation.
GnRH antagonists are initiated at approximately day 6 of
gonadotropin stimulation which begins on day 2-3 of a
menstrual cycle. This approach still requires awaiting menses
prior to initiating gonadotropins but decreases the interval
to oocyte retrieval compared to traditional IVF stimulation
protocols.
A recent report of 3 patients initiating “random start
IVF” evaluated the eﬀectiveness of initiating GnRH antago-
nists at the time of patient presentation (menstrual cycle day
11, 14, and 17) rather than waiting for menses. This was then
followed by the standard 10–14 days of ovarian stimulation
and subsequent oocyte retrieval. The goal was to decrease
the time to oocyte retrieval for breast cancer patients and
resulted in a reasonable ovarian response with 7–10 embryos
cryopreserved per patient [38]. This approach provides a
signiﬁcant advantage by decreasing total time for the IVF
cycle,butfurtherdataisneededtodetermineitseﬀectiveness
compared to traditional IVF stimulation regimens.
In addition to the delay in cancer treatment, ovarian
stimulation for IVF poses another theoretical risk to patients
with hormonally responsive cancers. Ovarian stimulation
with gonadotropins for IVF often results in supraphysiologic
estradiol levels of over 2000pg/mL compared to normal
physiologic peak estradiol levels of 200–350pg/mL. The high
estradiol levels sustained during IVF treatment are a partic-
ularconcerninwomenwithestrogenreceptorpositivebreast
cancer. In the initial nonrandomized studies, stimulation
protocols that include the selective estrogen receptor modu-
lator tamoxifen or aromatase inhibitors such as letrozole ad-
ministered during gonadotropin treatment have been shown
to decrease estradiol level production while not decreasing
overall oocyte numbers. Initial reassuring data indicates that
this approach has not been shown to increase short-term
cancer recurrences for breast cancer patients [39, 40].
Additionally, estradiol levels may be reduced after oocyte
retrieval by the use of GnRH agonists to trigger ovulation
instead of hCG. This has been shown to substantially reduce
the risk of ovarian hyperstimulation in patients undergoing
IVF by decreasing ovarian stimulation after retrieval. This
has been evaluated in oocyte donors undergoing oocyte
vitriﬁcation and has been shown in a retrospective study to
result in similar numbers of oocytes retrieved. There was
also no signiﬁcant diﬀerence in the percentage of oocytes
surviving thawing, oocyte fertilization, and pregnancy rates
[41]. Further research is needed to determine if this will be
beneﬁcial in cancer patients undergoing oocyte or embryo
banking but holds promise to further decrease any theoreti-
cal risks of breast cancer progression or recurrence as a result
of ovarian stimulation.
3.2.6. Additional Considerations. Counseling of patients for
future fertility should also include a discussion of alternative
options including third-party reproduction. Third-party re-
production includes the use of either oocytes donated by
another individual (either known or anonymously) as well
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Oocyte donation may be utilized for patients without
residual ovarian function after cancer treatment. Oocyte
donation enables a patient to conceive and carry a pregnancy
if she is unable to conceive with her own oocytes. Gestational
carriers are most commonly used for patients that do not
have a functional uterus to carry a pregnancy. They may
also be considered for patients that are concerned about
the recurrence of hormonally responsive tumors during
pregnancy or any increased risks of pregnancy complications
after cancer treatment. Adoption is also a consideration
for family building but may be more diﬃcult for cancer
survivors than patients without a history of cancer [42].
Unfortunately, a signiﬁcant barrier for many cancer
patients is the cost of fertility-preserving treatments. Insur-
ance coverage is often not provided for these treatments that
they are often considered “elective.” It has been argued that
insurance companies should provide coverage for iatrogenic
infertility as a result of cancer treatments similarly to
coverage provided for other iatrogenic postcancer treatment
conditions such as breast reconstruction after mastectomy
andwigsforalopecia[43].Theaveragecostoffertilitypreser-
vation for female cancer patients pursuing either embryo or
oocyte cryopreservation is $8655 [44] and remains a barrier
to access. Resources such as Fertile Hope’s Sharing Hope
Program can help patients and clinicians ﬁnd centers with
fertility preservation services as well as programs to provide
ﬁnancial assistance (http://www.fertilehope.org/).
Despite the concerns for patients including costs and
potential risks, a followup survey of 28 cancer survivors
who attempted fertility preservation found that 92.3% felt
positively about their decision to undergo fertility preser-
vation with only one patient, diagnosed with metastatic
cancer shortly after oocyte retrieval, expressing regret [45].
The fact that patients with cancer recurrence may die and
leave a minor child with one parent is an ethical concern.
It has been suggested that it may be unethical to enable a
woman to reproduce if she is expected to have a shortened
lifespan. A review of fertility preservation and reproduction
in cancer patients by the Ethics Committee of the Society
for Reproductive Medicine stated that this concern may not
be persuasive given that the risk of recurrence for many
patients may not be excessively high, and the child may have
a meaningful life despite the death of a parent [27].
3.3. Pregnancy after Cancer
3.3.1. Conceiving after Cancer and the Risk of Pregnancy Com-
plications. The likelihood of conceiving after cancer treat-
ments is dependent on the type of cancer, age at diagnosis,
treatments with gonadotoxic agents including type and
duration, and various other fertility factors. The chance for
conception at best can only be estimated based on individual
patient history and characteristics. It also appears that future
fertility may also be inﬂuenced by gender. Overall, the
likelihoodoffuturechildrenwasfoundtobelowerforfemale
cancer survivors than male survivors either spontaneously
or with fertility treatments [46]. When stratifying for age at
diagnosisandestimatingfromprobabilitycharts,menwitha
cancer diagnosis prior to age 30 years had the highest overall
chance of future parenthood (50%), followed by women
diagnosedatage30yearsoryounger(32%),thenmalesdiag-
nosed after age 30 years (12%), and then females diagnosed
after age 30 years (<5%). For female patients the likelihood
of pregnancy was dependent on the type of cancer and was
highest for patients after uterine choriocarcinoma (65%),
followed by lymphoma (23%) and malignant melanoma
(22%), all other cancers (<5%).
If pregnancy is established, there are several potential
risks to a fetus conceived after cancer treatment. Both
radiation and chemotherapy may induce chromosomal
aberrationsinoocytesthatmaytheoreticallyincreasetherisk
of birth defects and genetic disease in oﬀspring. A review of
studies evaluating the risk of malformations in oﬀspring of
breast cancer survivors did not report an increased risk of
birth defects compared with controls [47]. It may be that
any remaining pool of primordial follicles after treatments
is unaﬀected by the prior treatment, and/or those oocytes
that fertilize and develop into ongoing pregnancies are from
acohortofoocytesthatdonotdemonstrateanycarcinogenic
eﬀect. However, when considering the half-life of treatments
and the duration of time for oocyte maturation, it has been
recommended to delay pregnancy for at least 6 months [47]
after treatment with chemotherapy and 12 months following
completion of radiotherapy to minimize risks to oﬀspring
[48].
Pregnancy complications and the subsequent risk to the
fetus are another concern for cancer patients. A review of
pregnancies in patients previously treated for breast cancer
reported variable outcomes [47]. This meta-analysis evalu-
ated 6 studies reporting birth outcome data after breast can-
cer compared to women without breast cancer. Four studies
found no increased risk of any pregnancy complications;
however, one study reported a higher risk of miscarriage and
another reported no higher risk of miscarriage but a higher
risk of cesarean section, preterm birth, low birth weight,
delivery complications, and congenital abnormalities. The
authorsofthereviewsuggestthatalthoughthelargemajority
of births from women previously treated for breast cancer
had no adverse eﬀects, these women are at higher risk and
may need careful monitoring until additional studies resolve
the discrepancy in the data.
A recent report of birth outcomes obtained from a
childhood and adolescent cancer registry from 4 US regions
has reported that infants born to female childhood cancer
survivors were more likely to be preterm (RR 1.54), and to
weigh less than 2500g (RR 1.31). Although there appeared
to be a higher risk during the pregnancy, there were no
increased risks to the oﬀspring of malformations, infant
death, or altered sex ratio indicating no increased risk of
germ cell mutagenicity [49]. A review of pregnancies post-
cancer diagnosis in adults indicated that subsequent preg-
nancy did not represent a major health risk for the mothers
or children. In 678 pregnancies there were no increased risk
of congenital malformations (OR 0.6) though pregnancies
more often resulted in preterm delivery (OR 2.8), low birth
weight (adds ratio 2.5), and cesarean section (OR 2.3) and
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for multiple births from patients utilizing fertility treatments
to conceive [46].
It is not clear whether the increased risks in pregnancy
are related to the malignancy itself or the result of treatments
such as radiation or chemotherapy. Several considerations
exist in cancer patients that may aﬀect the risk to a develop-
ingfetusincludingalteredmetabolism,nutritiondeﬁciencies
frommalabsorptionofnutrients,increasedstress,andgener-
al overall decreased health. It is also possible that these
patients might be subjectively viewed as higher risk by their
physicians and are electively delivered earlier. In summary, it
does appear that there may be an increased risk of preterm
birth and associated neonatal complications for female can-
cer survivors, but the outcomes of the majority of pregnan-
cies appear similar to noncancer patients.
3.3.2. Risk of Transmission of Genetically Linked Cancers to
Oﬀspring. Although there does not appear to be a deﬁnitive
increasedriskofcongenitalabnormalitiesfortheoﬀspringof
female cancer patients, there is a concern over the transmis-
sionofgeneticallylinkedcancers.Hereditarycancersaccount
for about 5% of all malignancies [50]. Most hereditary can-
cersfollowanautosomaldominantmodeofinheritancewith
the most common being hereditary nonpolyposis colorectal
cancer, familial breast and ovarian cancer, neuroﬁbromatosis
type1,familialretinoblastoma,multipleendocrineneoplasia
type 2, and familial adenomatous polyposis. Fewer heredi-
tary cancers have an autosomal recessive inheritance such as
ataxia teleangiectatica and Fanconi anemia [51].
Preimplantation genetic diagnosis (PGD) is a technique
to screen embryos for genetically transmissible diseases prior
to implantation. PGD involves removing one or more cells
from an embryo after IVF and testing for predisposing
mutations. PGD may be performed for genetic diseases
where the gene has been identiﬁed and tested. PGD has been
performed for all of the cancer predisposition syndromes
mentioned previously in additional to several other less
common susceptibility syndromes [52].
Signiﬁcant controversy exists over the ethical aspects of
screening embryos for disease. A survey of 4,834 Americans
in 2004 found that approximately 52% of women and 62%
of men reported that they approved of PGD for screening
embryos that had a tendency to develop a disease such as
adult onset cancer [53]. A more recent survey of attendees
at a national conference for individuals and families aﬀected
by hereditary breast and ovarian cancer reported that only
32% of participants had ever heard of PGD; however,
57% believed that it was an acceptable option for high-
risk individuals and that patients should be given this in-
formation by their health-care provider [54]. The ASRM
Ethicscommitteeguidelinesstatethattheconcernsaboutthe
welfareofresultingoﬀspringshouldnotbecausefordenying
cancer patient’s assistance and that preimplantation genetic
diagnosis to avoid the birth of oﬀspring with a high risk of
inherited cancer is ethically acceptable. However, selection to
avoid a genetic disease may not always be appropriate and
factors such as the severity of the disease, the probability of
its occurrence, and the age at onset should be considered.
3.3.3. Pregnancy and Cancer Recurrence. Cancer is diagnosed
in one of every 118 pregnant women each year. There are
severalconcernsforpatientspursuingpregnancyaftercancer
treatment that may be dependent on the type of cancer and
treatments. Concerns include the risk of cancer recurrence
either during or after treatment, the possible increased risk
of cancer recurrence secondary to pregnancy itself (breast
cancer, endometrial cancer, and malignant melanoma), and
the diﬃculty in detecting cancer during pregnancy (breast
cancer and endometrial cancer).
For most cancers, future pregnancy does not negatively
impact the likelihood of recurrence. However, concern exists
for several hormonally mediated cancers due to the consid-
eration that the hormonal milieu of pregnancy may increase
the risk of recurrence. The most common female tumors in
reproductive age women that have been associated with hor-
monal mediators include breast cancer, endometrial cancer,
and malignant melanoma. The most common cancer in
womenofchildbearingageisbreastcancerandisparticularly
concerning due to its clear association with hormonal mark-
ers. Patients with estrogen and/or progesterone receptor-
positive tumors pose a particular challenge in counseling
patients regarding recurrence risks during pregnancy and
long-term overall recurrence risk.
Approximately 2% of all breast cancers occur in women
between 20 and 34 years of age and 11% in women between
35 and 45 years. Given the relatively young age at diagnosis
and initial treatment, there is a risk of recurrence during
the reproductive years. The overall risk of recurrence and
timing of recurrence in the context of pregnancy is diﬃcult
to evaluate due to the complex associations with other
predisposingfactorssuchasageatdiagnosis,priorpregnancy
history, age at menarche, and family history. Additional
considerationsincludewhetherornotpregnancyitselfaﬀects
the long term survival for patients with breast cancer, and
whether or not the timing of pregnancy aﬀects any risk of
recurrence.
Initial studies in the 1980s and early 1990s indicated that
there did not appear to be a diﬀerence in survival for time
intervals from diagnosis to pregnancy [55–57]. In contrast,
followup data indicated that patients that become pregnant
in the ﬁrst 3 months [58] or the ﬁrst 6 months [59]o ft h e
initial breast cancer diagnosis may have an increased mor-
tality. Clark et al. compared women that conceived within 6
months after a diagnosis of breast cancer to those patients
that became pregnant between 6 and 24 months and more
than 5 years after a diagnosis and found 5-year survival rates
of 54%, 78%, and 100%, respectively. Another population-
based study in 2006 showed a statistically nonsigniﬁcant
increased mortality risk (RR 2.20, P = 0.58) for women
diagnosed with breast cancer less than 6 months before
pregnancy. However, if the interval was more than 2 years,
the risk of death was reduced signiﬁcantly (RR 0.48, P =
0.009) [60].
A recent 2011 meta-analysis by Azim et al. has addressed
the optimal timing of pregnancy for breast cancer patients.
Five studies compared 353 patients who became pregnant
within 6–24 months and after 2 years of a breast cancer
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beyond 2 years did not have an eﬀect on overall outcome.
In summary, the data is controversial but it would appear
prudent to advise waiting a minimum of 6 months after
diagnosis to attempt pregnancy but more than 2 years is
perhaps advisable and will depend on individual patient
characteristics. For patients at higher risk of recurrence, a
delay of 5 years or more may also be recommended.
Interestingly, several studies have suggested that preg-
nancyisactuallyassociatedwithabetterlong-termprognosis
for breast cancer patients. The Azim et al. meta-analysis
reviewed 14 studies of women who became pregnant after
breast cancer and reported that 8 studies demonstrated a
signiﬁcant survival advantage while the remaining 6 showed
a trend-favoring pregnancy but did not reach statistically
signiﬁcance [61], Once criticism of studies reporting an
improved survival for patients with breast cancer is that they
may have included selection bias referred to as the “healthy
mother eﬀect.”
The “healthy mother eﬀect” infers that women who
become pregnant represent an overall healthier group of
patients with perhaps a lower risk of disease relapse. The
Azim et al. meta-analysis incorporated several sensitivity
analyses to attempt to control for the “healthy mother eﬀect”
but still reported that women who got pregnant following
breast cancer diagnosis had a 41% reduced risk of death
compared to women who did not get pregnant and was most
notableinpatientswithahistoryofnode-negativedisease.In
a subgroup analysis, they compared the outcome of women
with a history of breast cancer that became pregnant to
breast cancer patients who did not get pregnant and did not
ﬁnd a diﬀerence in survival between the groups. A separate
meta-analysisalsocontrollingforthe“healthymothereﬀect”
also found similar results with a survival that was higher
amongearlystagebreastcancerpatientscomparedtocontrol
(hazard ratio 0.51) for pregnancy that occurred at least 10
months after the diagnosis [62].
The mechanism by which pregnancy may provide a
protective eﬀect is not clearly understood. It has been found
that parous women have changes in expression of markers
of disease recurrence including estrogen receptor alpha
and beta (ERα,E R β) and human epidermal growth factor
receptor 2 (HER2) for up to 10 years after pregnancy,
which may provide protection from cancer recurrence [63].
Patterns of breast cancer recurrence have been evaluated
with regard to estrogen receptor status in two randomized
trials with 25 years of median followup. It was reported
that most breast cancer recurrence occurred within the ﬁrst
5–7 years in ER-negative after randomization while ER-
positive patients hadevents spreadthrough 10 years.Patients
with ER-positive breast cancer generally receive 5 years of
adjuvant hormonal therapy and are recommended to delay
childbearing although some women may elect to interrupt
hormonaltherapytoconceive.Evenforpatientsthatmaynot
be receiving adjuvant hormonal therapy, it is recommended
that patients wait a minimum of 2 years following diagnosis
to conceive due to a generally higher incidence of recurrence
in the ﬁrst 2 years after diagnosis [64]. Overall, available
data support that pregnancy after breast cancer are safe for
women at low risk of recurrence but the timing of pregnancy
will depend on individual patient characteristics and estro-
gen receptor status.
Although less common than breast cancer, malignant
melanoma is a cancer with a peak incidence in the 30s
and 40s resulting in a substantial number of women in
their reproductive years interested in pursuing pregnancy
after treatment. In contrast to breast cancer, there is limited
evidence that hormonal mediators signiﬁcantly inﬂuence
this cancer. It has been noted that patients diagnosed during
pregnancy often have a more rapid progression of their
cancer, and estrogen-receptor proteins have been detected
in tumor specimens. However, most studies have not found
a statistical diﬀerence in 5-year survival rate for pregnant
or nonpregnant patients. A study investigating endocrine
ablation with procedures such as oophorectomy on patients
with melanoma showed no beneﬁt [65]. However, this
author does suggest advising against future pregnancies for
patients with nodal metastases or those who experienced
tumor activation during a prior pregnancy. Others have
recommended that all women with a history of melanoma
avoid pregnancy for 3–5 years after treatment [66].
Endometrialcancerisanotherhormonallymediatedcan-
cer as evidence by the fact that exposure to unopposed estro-
gen is a signiﬁcant predisposing factor. Progesterone oﬀers
ap r o t e c t i v ee ﬀect on the endometrium but both estrogen
and progesterone are elevated during gestation. Limited data
is available regarding absolute risk of cancer progression or
recurrence for patients with a history of endometrial cancer
as most patients are treated with a hysterectomy. A small
case series and literature review of 50 women reported data
on women with early stage endometrial cancer treated with
conservative hormonal treatment in lieu to a hysterectomy.
There were 65 deliveries reported with 77 live births. No
neonatal morbidity was noted but one of the 50 women
died of her disease after delivery [67]. Another study found
that 40% of patients treated with conservative treatment of
progestin therapy conceived but had a 36% relapse rate of
their cancer [68].
4. Conclusions
Given the relatively high incidence of cancer in reproduc-
tive age women and improvements in 5-year survival, an
increasingnumberofwomenarepresentingfordiscussionof
fertility preservation and pregnancy after cancer treatment.
The ASCO published recommendations in 2006 on fertility
preservation in cancer patients. These guidelines state that
oncologists should address the possibility of infertility with
cancer patients and be prepared to discuss possible fertility
preservation options or refer the patient to a reproductive
specialist.
Part of the diﬃculty in counseling patients regarding
the risk of infertility and/or subsequent pregnancy compli-
cations is that the risks are dependent on several factors.
Theserisksincludethedoseanddurationoftreatment,other
risk factors for infertility, the age of the patient, and the
patient’s baseline ovarian reserve at the time of initiation of
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counsel patients about the impact of their cancer treatments
on fertility and chances for future pregnancy.
Fertility preservation is a rapidly evolving ﬁeld that
includes medical and surgical treatments to decrease the im-
pact of cancer treatments on future fertility. Ongoing trials
will address the eﬀectiveness of GnRH agonists in protecting
ovarian reserve. Several technologies exist to help preserve
future fertility including embryo cryopreservation, oocyte,
and ovarian tissue cryopreservation. Embryo cryopreserva-
tion is currently the only recommended method of gamete
preservation, but recent advances in oocyte vitriﬁcation may
increase the utility of this treatment for cancer patients.
Additionally, PGD may decrease the risk of disease transmis-
sion of hereditary cancer syndromes. The risk to the patient
of IVF may also be decreased with recent advances in IVF
stimulation protocols.
Theremaybeanincreasedriskofpretermbirthandasso-
ciated neonatal complications for female cancer survivors,
buttheoutcomesofthemajorityofpregnanciesappearsimi-
lartononcancerpatients.Itisnotclearwhethertheincreased
risks in pregnancy are related to the malignancy itself or the
result of treatments such as radiation or chemotherapy. Also,
the risk of disease recurrence will depend on several factors,
but for most cancers the risk of recurrence is not increased
secondary to pregnancy. Overall, pregnancy appears safe for
most patients after cancer treatment but will depend on
individual patient characteristics.
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